VA data reveals who gets relugolix for prostate cancer
NCT ID NCT06462014
First seen Dec 12, 2025 · Last updated May 25, 2026 · Updated 22 times
Summary
This study analyzed medical records of 507 prostate cancer patients from the Veterans Affairs health system who started taking relugolix. Researchers looked at where patients lived, what other treatments they had, and their overall health. The goal was to describe the types of patients receiving this medication in everyday practice, not to test if the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.